2.8 Medication Reconciliation & Ordering Monitoring Procedures

Medication Reconciliation & Ordering Monitoring Procedures

Medication reconciliation and laboratory monitoring sit at the intersection of clinical judgment and California practice authority. Outline tasks 2A13 and 2A14 expect you to build an accurate medication list, resolve discrepancies before harm occurs, and ensure the right labs or diagnostic tests are ordered, interpreted, and communicated. On the CPJE, scenarios often combine a transition-of-care miss with a monitoring gap—treat both as pharmacist-owned problems.

Medication Reconciliation: Process and High-Risk Focus

Medication reconciliation is a structured comparison of a patient’s best possible medication history (BPMH) against medication orders at every transition of care: admission, transfer between units or levels of care, and discharge. The goal is not a clerical copy of what was on the last discharge summary; it is a verified, current list of what the patient was actually taking, then an intentional decision to continue, hold, modify, or discontinue each agent.

Building the Best Possible Medication History

Effective reconciliation draws from multiple sources because no single source is complete:

1. Patient or caregiver interview — ask about prescription drugs, OTC products, herbals/CAM, injectables, inhalers, eye drops, patches, and as-needed medications with actual doses and frequencies.
2. Pharmacy fill history / PDMP (CURES) — especially useful for controlled substances and recent opioid or benzodiazepine patterns.
3. Prior discharge summaries, ambulatory EHR medication lists, and bottle/photo review when available.
4. Allergy and ADR history — distinguish true hypersensitivity from intolerance so clinically needed drugs are not permanently blocked.

Document unresolved discrepancies (e.g., patient reports taking warfarin 5 mg daily but home list shows 2.5 mg) and escalate before the wrong dose is continued in the hospital.

High-Risk Hospitalized Patients

The outline specifically flags high-risk hospitalized patients. Heighten scrutiny when the regimen includes:

• Anticoagulants / antiplatelets — wrong hold or restart timing drives thrombosis or bleeding.
• Insulin and other hypoglycemics — home basal rates often do not translate 1:1 to inpatient nutrition and illness.
• Opioids, benzodiazepines, and other CNS depressants — risk of respiratory depression, especially with new sedatives.
• Narrow therapeutic index drugs — digoxin, lithium, phenytoin, aminoglycosides, vancomycin, immunosuppressants.
• Renally cleared high-alert agents in AKI or fluctuating CrCl.

Classic CPJE traps include continuing a home ACE inhibitor and diuretic during acute kidney injury, missing that a patient was on a DOAC at home when bridging with heparin, or restarting a full home opioid regimen in an opioid-naïve postoperative patient after a prolonged NPO period. At discharge, reconciliation must produce a clear list for the patient and the next provider: what changed, why, and what monitoring is still pending.

Recommending and Ordering Monitoring Procedures

Outline task 2A14 covers recommending or ordering monitoring such as renal/hepatic function, glucose, EKG, and drug levels. Monitoring is part of determining and managing the course of therapy—not an optional add-on.

Drug-Specific Monitoring Anchors

Therapeutic drug monitoring fails when the level is drawn at the wrong time (e.g., a “trough” drawn during an infusion) or when the number is filed without action. Always interpret levels with renal function, interacting drugs, and the patient’s clinical response.

California Authority to Order and Interpret Tests

California law explicitly supports pharmacist involvement in monitoring. Under Business and Professions Code (B&P) § 4052, pharmacists may order and interpret tests for the purpose of monitoring and managing the efficacy and toxicity of drug therapies, performed in the course of treating a patient and in accordance with policies, procedures, or protocols of the applicable practice setting as required by statute. Related provisions expand the operational frame:

• B&P § 4052.1 — in licensed health care facilities, pharmacists may perform specified clinical functions, including ordering drug therapy–related laboratory tests, pursuant to facility policies and appropriate training.
• B&P § 4052.2 — similar collaborative/protocol-based functions in health care facilities, home health agencies, or clinics with physician oversight.
• B&P § 4052.6 / § 4210 (Advanced Practice Pharmacist) — APh recognition expands authority to perform patient assessments and to order and interpret tests as part of advanced practice pharmacy, often paired with initiating, adjusting, or discontinuing drug therapy under collaborative agreements or authorized protocols.

Exam distinction: recommending a test to a prescriber is always within clinical practice. Independently ordering and interpreting tests is authorized in California when the pharmacist is acting within § 4052 and the applicable facility protocol, CPA, or APh scope—do not invent unlimited standalone diagnostic authority outside those frameworks. CLIA-waived point-of-care testing in pharmacies has additional licensing and training requirements when performed on-site.

Communicating Results and Closing the Loop

Ordering a lab without acting on it is a process failure. When results return:

1. Interpret in context — is the vancomycin AUC/trough high because of AKI, a drug interaction, or a mistimed draw?
2. Communicate to the care team — contact the prescriber or use the shared EHR with a clear recommendation (hold, reduce, repeat level, obtain ECG).
3. Inform the patient or representative when results change self-management (e.g., home INR plan, hypoglycemia precautions), consistent with counseling duties and care-setting rules.
4. Document the result, your clinical assessment, who was notified, and the agreed plan.

For hospitalized high-risk patients, reconciling the discharge medication list with pending monitoring (e.g., “repeat BMP in 3 days after starting spironolactone”) prevents ambulatory harm. In community practice, the same discipline applies when initiating pharmacist-furnished therapies or managing chronic medications under protocol: baseline labs, timed follow-up, and documented communication complete the monitoring cycle.